About Casebia

About Casebia

Scaled for Success

Pioneering a new field of medicine requires more than vision. It takes a long-term commitment, sufficient resources and a collaborative approach to seize on the emerging breakthroughs that will define the future.

Casebia Therapeutics, a 50-50 joint venture between CRISPR Therapeutics and Bayer, was created to accelerate the field of gene editing therapeutics today, and for the long haul. Drawing on CRISPR/Cas9 technology and expertise from CRISPR Therapeutics and the distinctive disease know-how and protein engineering capabilities of Bayer, we are working to redefine what's possible for patients with a wide range of inherited diseases.

Read more read more




Axel Bouchon, Ph.D. (chair)
Head of Bayer Lifescience Center Bayer AG
Rodger Novak, M.D.
Chief Executive Officer and Founder CRISPR Therapeutics
Sven Ante (Bill) Lundberg, M.D.
Chief Scientific Officer CRISPR Therapeutics
Andreas Busch, Ph.D.
Head of Drug Discovery Bayer Pharmaceuticals